USP–NF Updates

- Two New Revision Bulletins (posted 28–Feb–2020)
- Three New Pending Notices of Intent to Revise (posted 28–Feb–2020)
- Three New Notices of Intent to Revise (posted 28–Feb–2020)
- One New Publication Announcement (posted 28–Feb–2020)
- One New General Announcement (posted 28–Feb–2020)
- Cumulative List Updated (posted 28–Feb–2020)

USP–NF Components

*USP–NF* is a combination of two compendia, the United States Pharmacopeia (USP) and the National Formulary (*NF*). Monographs for drug substances, dosage forms, and compounded preparations are featured in the USP. Monographs for dietary supplements and ingredients appear in a separate section of the USP. Excipient monographs are in the *NF*.

Monographs

A monograph includes the name of the ingredient or preparation; the definition; packaging, storage, and labeling requirements; and the specification. The specification consists of a series of tests, procedures for the tests, and acceptance criteria. These tests and procedures require the use of official [USP Reference Standards](https://www.usp.org). Medicinal ingredients and products will have the stipulated strength, quality, and purity if they conform to the requirements of the monograph and relevant general chapters.

- View a sample *USP–NF* monograph.

General Chapters

Tests and procedures referred to in multiple monographs are described in detail in the *USP–NF* general chapters.

General Notices
The General Notices provide definitions for terms used in the monographs, as well as information that is necessary to interpret the monograph requirements.

**Official Recognition**

The U.S. Federal Food, Drug, and Cosmetics Act designates the *USP–NF* as official compendia for drugs marketed in the United States. A drug product in the U.S. market must conform to the standards in *USP–NF* to avoid possible charges of adulteration and misbranding. [Learn more.]

**Standards Established through a Public Process**

USP creates and continuously revises *USP–NF* standards through a unique public–private collaborative process, which involves pharmaceutical scientists in industry, academia, and government as well as other interested parties from anywhere in the world.

[Warning Notice about *USP–NF* on Unauthorized Websites]